PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial

MLA

Paul B. Chapman, et al. “PLX4032 (RG7204), a Selective Mutant RAF Inhibitor: Clinical and Histologic Characteristics of Therapy-Associated Cutaneous Neoplasms in a Phase I Trial.” Journal of Clinical Oncology, vol. 28, May 2010, p. 8592. EBSCOhost, https://doi.org/10.1200/jco.2010.28.15_suppl.8592.

APA

Paul B. Chapman, Rebecca Lee, K. B. Kim, K. B. Nolop, Madeleine Duvic, Grant A. McArthur, A. Ribas, Keith T. Flaherty, J. A. Sosman, & Mario E. Lacouture. (2010). PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. Journal of Clinical Oncology, 28, 8592. https://doi.org/10.1200/jco.2010.28.15_suppl.8592

Chicago

Paul B. Chapman, Rebecca Lee, K. B. Kim, K. B. Nolop, Madeleine Duvic, Grant A. McArthur, A. Ribas, Keith T. Flaherty, J. A. Sosman, and Mario E. Lacouture. 2010. “PLX4032 (RG7204), a Selective Mutant RAF Inhibitor: Clinical and Histologic Characteristics of Therapy-Associated Cutaneous Neoplasms in a Phase I Trial.” Journal of Clinical Oncology 28 (May): 8592. doi:10.1200/jco.2010.28.15_suppl.8592.